Cargando…

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

BACKGROUND: Advanced biliary tract carcinoma has a very poor prognosis, with chemotherapy being the mainstay of treatment. Sorafenib, a multikinase inhibitor of VEGFR-2/-3, PDGFR-β, B-Raf, and C-Raf, has shown to be active in preclinical models of cholangiocarcinoma. METHODS: We conducted a phase II...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bengala, C, Bertolini, F, Malavasi, N, Boni, C, Aitini, E, Dealis, C, Zironi, S, Depenni, R, Fontana, A, Del Giovane, C, Luppi, G, Conte, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813746/ https://www.ncbi.nlm.nih.gov/pubmed/19935794 http://dx.doi.org/10.1038/sj.bjc.6605458

Ejemplares similares

Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy
por: Bengala, C, et al.
Publicado: (2010)

FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer
por: Bertolini, F, et al.
Publicado: (2011)

Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report
por: Malavasi, Norma, et al.
Publicado: (2009)

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
por: Lee, J K, et al.
Publicado: (2013)

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
por: André, T, et al.
Publicado: (2008)

Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
por: Galli, L, et al.
Publicado: (2007)

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011)

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
por: Eisen, T, et al.
Publicado: (2006)

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
por: Hezel, A F, et al.
Publicado: (2014)

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
por: Larkin, J M G, et al.
Publicado: (2010)

Phase II study of S-1 in patients with advanced biliary tract cancer
por: Ueno, H, et al.
Publicado: (2004)

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
por: Hack, Stephen P., et al.
Publicado: (2021)

Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study
por: Mouriaux, F, et al.
Publicado: (2016)

Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma
por: Bengala, C, et al.
Publicado: (2005)

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
por: Harder, J, et al.
Publicado: (2006)

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study
por: Bajetta, E, et al.
Publicado: (2007)

Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer
por: Matsuyama, Masato, et al.
Publicado: (2014)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
por: El-Khoueiry, A B, et al.
Publicado: (2014)

Appropriate number of biliary biopsies and endoscopic retrograde cholangiopancreatography sessions for diagnosing biliary tract cancer
por: Takagi, Tadayuki, et al.
Publicado: (2019)

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity
por: Kim, K-p, et al.
Publicado: (2011)

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
por: Yau, Thomas, et al.
Publicado: (2012)

Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment
por: Kim, Richard, et al.
Publicado: (2017)

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
por: Fornaro, L, et al.
Publicado: (2014)

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
por: Suzuki, Eiichiro, et al.
Publicado: (2013)

Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
por: Valle, J W, et al.
Publicado: (2009)

Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study
por: Tibaldi, C, et al.
Publicado: (2006)

A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates
por: Ott, Patrick A., et al.
Publicado: (2010)

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
por: Steinbild, S, et al.
Publicado: (2007)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
por: Goff, Laura W., et al.
Publicado: (2016)

Minimally Invasive Management of Acute Biliary Tract Disease during Pregnancy
por: Chiappetta Porras, Luis Tomás, et al.
Publicado: (2009)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
por: Hottinger, A F, et al.
Publicado: (2014)

Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)
por: Javle, M.M., et al.
Publicado: (2021)

Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer
por: Cardin, Dana B, et al.
Publicado: (2014)

The impact of peritoneal lavage cytology in biliary tract cancer (KHBO1701): Kansai Hepato‐Biliary Oncology Group
por: Matsukuma, Satoshi, et al.
Publicado: (2020)

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials
por: Eckel, F, et al.
Publicado: (2007)

Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases
por: Leelawat, Kawin, et al.
Publicado: (2011)

Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers
por: Mizrahi, Jonathan D, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mi5enb80f0v8j7cf0dcqmbs73n